Description
Latin name
ISONIAZID-DARNITSA
Release form
Injection.
packaging 10 pcs
Indications
Treatment of all forms of active tuberculosis, including tuberculous meningitis (as part of combination therapy). Prevention of tuberculosis in people who are in close contact with tuberculosis patients in people with a positive skin reaction (more than 5 mm) for tuberculin and X-ray data indicating non-progressive tuberculosis in children under 4 years of age with a positive reaction to tuberculin (more than 10 mm) and increased risk of dissemination.
Contraindications
Epilepsy, history of seizures and polio, impaired liver and / or kidney function, atherosclerosis.
Use during pregnancy and lactation
Isoniazid may be used during pregnancy and lactation (breastfeeding). Isoniazid crosses the placental barrier, excreted in breast milk.
Composition of
1 ampoule with 5 ml of injection contains 500 mg of isoniazid.
Dosage and administration of
V / m, at 0.005-0.012 g / kg of body weight per day, course of 2-6 months. In / in (within 30-60 s), 0.01-0.015 g / kg / day of 10% solution, course – 30-150 infusions.
Drug Interactions
Compatible with all anti-TB drugs (except cycloserine), the likelihood of side effects is reduced when combined with vitamins B6 and glutamic acid.
Storage Conditions
In a dark place, at a temperature of 5 45 ° C.
Expiration
2 years.
conditions granted through pharmacies
Prescription
Dosage form
solution for injection
Russia, Russia, Russia biosynthesis